Intrinsiqq
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. Financials

MLYS

Compare

All currency values in $ millions unless otherwise noted

Income Statement
DEC 2025
~1.4:1 split
DEC 2024
~1.3:1 split
DEC 2023
7:1 split
DEC 2022
General & Administrative$39$24$14$5
Research & Development$132$169$70$26
Total Operating Expenses$171$192$85$31
Operating Income-$171-$192-$85-$31
Other Non-Operating Income (Expense)$16$15$13$2
Income Tax Expense$0–––
Net Income
Net Income-$155-$178-$72-$30
EPS (Basic)-$2.29-$3.66-$1.99-$5.77
EPS (Diluted)-$2.29-$3.66-$1.99-$5.77
Weighted Avg Shares (Basic)67.7M48.5M36.2M5.2M
Weighted Avg Shares (Diluted)67.7M48.5M36.2M5.2M
Shares Outstanding67.7M48.5M36.2M5.2M

Mineralys Therapeutics (MLYS) financials: revenue, profit and margins

Mineralys Therapeutics (MLYS) generated about n/a in revenue and -$370 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Mineralys Therapeutics profitable?+

Mineralys Therapeutics reported about -$370 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 29 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 5 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MLYS

CompareIntrinsic value
INVAInnoviva Inc.
$18.41+0.00%60
PAHCPhibro Animal Health Corporation
$33.29-2.32%57
NUVBNuvation Bio Inc.
$3.80-0.26%10
RAREUltragenyx Pharmaceutical Inc.
$16.48-4.30%40
PRGOPerrigo Company plc
$15.94-0.62%17
RCUSArcus Biosciences Inc.
$15.62-1.01%10
XNCRXencor Inc.
$33.26-2.21%11
VRDNViridian Therapeutics Inc.
$29.93-4.80%40

Held by ETFs

MLYS is in 37 US ETFs. The largest of them, with MLYS's weight in each:

Spot a number that looks wrong? Check it in MLYS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing MLYS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.